Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights the potential of permeation enhancers to improve the delivery of active ingredients across the skin, optimizing therapeutic outcomes despite challenges posed by individual variability and environmental factors, according to the authors' analysis of current understanding and applications in skincare and transdermal therapies.

This case report describes a 7-year-old boy with alopecia areata and reduced vitamin D receptor expression whose condition improved after using calcipotriol, a strong vitamin D analog.

This study found that Transcutol-containing vesicles improved the delivery of minoxidil to deeper skin layers in vitro but did not facilitate its permeation through the skin.

This study reports that poliosis can be an adverse effect of topical prostaglandin F2α analog therapy in patients treated for primary open angle glaucoma.

This study found that twice-daily application of 3% topical minoxidil maintained a higher nonvellus hair count compared to once-daily application over 2 years and 9 months in men with male pattern baldness.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study found that applying dinitrochlorobenzene (DNCB), a contact allergen, led to hair regrowth in patients with alopecia areata, while croton oil did not have the same effect.

In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

This paper reviews strategies to enhance the effectiveness of topical drug delivery by addressing skin barrier challenges, optimizing drug delivery systems, and personalizing treatment approaches, highlighting both current advancements and limitations in the field.

This study found that combining microneedling with PRP and topical minoxidil (5%) significantly improved hair growth in men with androgenetic alopecia compared to using minoxidil alone.

This study found that minoxidil-loaded niosomes with a Span 60 and cholesterol ratio of 1:2 significantly increased skin retention of minoxidil compared to control gel.

This study found that dutasteride-loaded nanostructured lipid carriers coated with a stearic acid-chitosan oligomer are stable, less cytotoxic, and suitable for topical delivery to promote hair growth.

This study found no protective effect of topical calcipotriol on hair loss in chemotherapy patients, and the authors propose the term "atrophic telogen effluvium" for this type of hair loss.

This study found that chitosan microparticles containing minoxidil sulphate sustained its release and may hold potential for targeted topical treatment of alopecia.

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.

This study found that topical minoxidil increased heart rate and had significant effects on cardiac volumes and mass compared to placebo, but its long-term safety remains uncertain.

This study reported that 1% bexarotene gel was well tolerated and possibly effective for inducing partial hair regrowth in alopecia areata, but more rigorous trials are needed to confirm its efficacy.

In this study, five women with androgenetic alopecia experienced severe facial and limb hypertrichosis after using 5% topical minoxidil, which resolved after discontinuing the treatment.

This study found that topical minoxidil solutions showed the highest skin permeation at 3-4% concentrations, with crystallization occurring at a 5% concentration due to vehicle component evaporation.

This study found that both 2% and 3% topical minoxidil were more effective than placebo in promoting hair growth for men with male pattern baldness over 12 months.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

This study found that DPCP treatment led to cosmetically acceptable hair regrowth in 38% of patients with chronic severe alopecia areata, while adding 5% minoxidil showed no significant clinical benefit.

This study observed that 2% minoxidil solution was at least as effective as 3% for increasing hair growth and stabilizing bald areas in men with male pattern baldness.

In this study, niacinamide 4% and desonide 0.05% emulsions significantly improved axillary hyperpigmentation in women, with desonide demonstrating a superior depigmenting effect compared to niacinamide and placebo.

This article reports two cases where 2% topical minoxidil showed promise in treating traction alopecia, but it does not offer broader clinical conclusions.

This review found topical ketoconazole to be highly effective against Malassezia-related skin conditions, though other treatments may outperform it for Tinea and Candida infections.

This study found that topical calcipotriol lotion resulted in hair regrowth in 59.1% of alopecia areata patients, with better response observed in those with lower serum vitamin D levels.

This study found that topical melatonin solution was associated with positive effects on hair density and reduction in hair loss for androgenetic alopecia, with good tolerability reported in several clinical trials.